Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Aug 20:16:62-64.
doi: 10.1016/j.jdcr.2021.08.012. eCollection 2021 Oct.

Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis

Ronan Talty  1   2 , William Damsky  1   2 , Brett King  1
Affiliations
Case Reports

Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis

Ronan Talty et al. JAAD Case Rep. .
No abstract available

Keywords: JAK; JAK inhibitor; JAK, Janus kinase; JAK-STAT; Janus kinase; STAT, signal transducer and activator of transcription; sarcoidosis; tofacitinib.

PubMed Disclaimer

Conflict of interest statement

Dr King has served on advisory boards and/or is a consultant and/or is a clinical trial investigator for AbbVie, Aclaris Therapeutics Inc, AltruBio Inc, Almirall, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly and Company, Incyte Corp, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio. He is on speaker bureaus for Pfizer Inc, Regeneron, and Sanofi Genzyme. Dr Damsky has received research funding from 10.13039/100004319Pfizer, is a consultant for Eli Lilly and Twi Biotechnology, and receives licensing fees from EMD/Sigma/Millipore in unrelated work. Author Talty has no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Clinical images of cutaneous involvement (A) at presentation, (B) after 3 months of tofacitinib, and (C) after 6 months of tofacitinib.
See this image and copyright information in PMC

References

    1. Yanardaǧ H., Pamuk O.N., Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med. 2003;97(8):978–982. - PubMed
    1. Zhou T., Casanova N., Pouladi N. Identification of JAK-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci Rep. 2017;7(1):4237. - PMC - PubMed
    1. Li H., Zhao X., Wang J., Zong M., Yang H. Bioinformatics analysis of gene expression profile data to screen key genes involved in pulmonary sarcoidosis. Gene. 2017;596:98–104. - PubMed
    1. Damsky W., Thakral D., Emeagwali N., Galan A., King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540–2546. - PMC - PubMed
    1. Damsky W., Thakral D., McGeary M.K., Leventhal J., Galan A., King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612–621. - PMC - PubMed

Publication types

LinkOut - more resources